Di Che Pharmaceutical (688192.SH): Shuo Zhe and Gao Rui Zhe multiple research results selected for the 2025 World Lung Cancer Conference.

23/07/2025

DiZhe Pharmaceutical (688192.SH) announced that the company will hold a conference in Barcelona, Spain from September 6th to 9th, 2025.

Di Zhe Medical (688192.SH) announced that the company will present its independently developed new lung cancer targeted drug Shuwozhe (ZEGFROVY, generic name: Shuwotini tablets) and highly selective JAK1 inhibitor Gaorizhe (generic name: Golixetini capsules) at the 2025 World Lung Cancer Congress (WCLC) in Barcelona, Spain from September 6th to 9th, 2025. The company will announce multiple latest research results in non-small cell lung cancer. Among them, the latest data from the international multicenter registered clinical trial of Shuwozhe "Wukong 1B" (WU-KONG1B) has been selected for an oral presentation.

Wall Street giants are focusing on digital assets: Goldman Sachs Group, Inc. (GS.US) is teaming up with New York TrustCo Bank Corp NY (BK.US) to launch a $7.1 trillion tokenized currency market fund channel.

PANGAEA CONNECT (01473) will resume trading from July 24th.

CITIC SEC: Hainan Customs Closure Time Confirmed. It is recommended to pay attention to tourism industry companies that will benefit in the long term under the customs closure policy.

PANGAEA CONNECT (01473) will resume trading from July 24th.

CITIC SEC: Hainan Customs Closure Time Confirmed. It is recommended to pay attention to tourism industry companies that will benefit in the long term under the customs closure policy.